Literature DB >> 33403170

Physostigmine in Anticholinergic Poisoning: An Old Antidote With Resurgence.

Nicholas G Blackstone1, April Olson1, Bujji Ainapurapu1.   

Abstract

Physostigmine is a cholinesterase inhibitor used therapeutically in patients with anticholinergic delirium that is so severe that intubation may be required for airway protection. Given that a wide variety of medications have anticholinergic properties, and the current standard of care is typically a central nervous system depressant, hospitalizations are often lengthy and normally require a critical-care level of attention. Despite this, physostigmine is often underutilized and poorly understood in the clinical setting. We report a case of a 43-year-old female who presented to the emergency department one hour after ingesting approximately 150 tablets of diphenhydramine in a suicide attempt. She was treated with benzodiazepines with minimal success, and airway protection became imminent as her mentation continued to decline. Through the use of physostigmine, we were able to save this patient from endotracheal intubation and the potential complications of mechanical ventilation.
Copyright © 2020, Blackstone et al.

Entities:  

Keywords:  anticholinergic delirium; anticholinergic overdose; physostigmine

Year:  2020        PMID: 33403170      PMCID: PMC7773307          DOI: 10.7759/cureus.11739

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  7 in total

Review 1.  Adverse Effects of Physostigmine.

Authors:  Ann M Arens; Tom Kearney
Journal:  J Med Toxicol       Date:  2019-02-11

Review 2.  Safety and effectiveness of physostigmine: a 10-year retrospective review<sup/>.

Authors:  Ann M Arens; Krishna Shah; Suad Al-Abri; Kent R Olson; Tom Kearney
Journal:  Clin Toxicol (Phila)       Date:  2017-07-13       Impact factor: 4.467

3.  A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning.

Authors:  M J Burns; C H Linden; A Graudins; R M Brown; K E Fletcher
Journal:  Ann Emerg Med       Date:  2000-04       Impact factor: 5.721

4.  A Comparison of Resource Utilization in the Management of Anticholinergic Delirium Between Physostigmine and Nonantidote Therapy.

Authors:  Sean P Boley; Samuel J Stellpflug
Journal:  Ann Pharmacother       Date:  2019-04-25       Impact factor: 3.154

5.  Timing and frequency of physostigmine redosing for antimuscarinic toxicity.

Authors:  Christopher Rosenbaum; Steven B Bird
Journal:  J Med Toxicol       Date:  2010-12

6.  Asystole complicating physostigmine treatment of tricyclic antidepressant overdose.

Authors:  P Pentel; C D Peterson
Journal:  Ann Emerg Med       Date:  1980-11       Impact factor: 5.721

Review 7.  Pharmacological management of anticholinergic delirium - theory, evidence and practice.

Authors:  Andrew H Dawson; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.